Claim Missing Document
Check
Articles

B Cell-Activating Factor (BAFF) and Ubiquitin Enzyme A20 as Functional Proteins in Targeted Therapy on Patients with Systemic Lupus Erythematosus Fajar, Desi Reski; Rostinawati, Tina; Hamijoyo, Laniyati; Barliana, Melisa Intan
The Indonesian Biomedical Journal Vol 16, No 5 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i5.3161

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation. The pathogenesis of SLE involves key proteins, including B cell-activating factor (BAFF) and the ubiquitin enzyme A20, both serving as negative regulators of inflammation and contributing to B cell homeostasis. In this review, focused on interventions directed at BAFF and the A20 enzyme, utilizing monoclonal antibodies either independently or in conjunction with conventional therapy for SLE patients.METHODS: A literature search was conducted on the PubMed platform by combining various terms, including "B-cells activating factor", "TNFAIP3 protein (human)", "therapeutics" or "drug therapy", and "lupus erythematosus, systemic" (limited to the last 10 years). From total of 104 articles discovered in thr search, the total number of articles collected after being filtered was 27 articles.RESULTS: Clinical development and evaluation have been conducted regarding the use of appropriate therapy for SLE patients. Selective BAFF inhibitor has been tested in clinical trials as a blocking agent in BAFF receptor (BAFF-R) and signaling nuclear factor-kappaB (NF-κB) by A20 bindings to inhibit the activation of autoreactive B cells. Just like other antimonoclonal therapies, BAFF and the A20 enzyme can be used as therapeutic targets with a single use or combined with the standard therapy in patients with SLE. In addition, the use of BAFF and A20 also shown to have safe side effects in patients with SLE. CONCLUSION: BAFF protein and A20 enzyme present promising therapeutic targets for managing autoimmune diseases like SLE. Therapeutic interventions can be administered individually or in conjunction with standard treatments.  KEYWORDS: systemic lupus erythematosus, therapeutic targets, BAFF, A20
Co-Authors Abdurahman Ridho Afifah, Nadya Nurul AGATHA VIKA PURWANINGTYAS Ahmad Faried Ahmad Muhtadi Ajeng Diantini, Ajeng Aliya Nur Hasanah Among, Sayyid Andi Wijaya Andi Wijaya ANDI WIJAYA Angliana Chouw, Angliana Anna Meiliana Anna Meiliana ARNANDA, QUINZHEILLA PUTRI Balqist, Syara Nur Fitri Bonor, Toga Chandra Agung Purnama Cissy Bana Kartasasmita Cynthia Retna Sartika, Cynthia Retna Dedi Suyatno Dewi Muliaty Didi Susanto Driyanti Rahayu Edhyana Sahiratmadja Effendi, M. Fariz ELLENA MAGGYVIN Erizal Sugiono Eva Feriadi Fajar, Desi Reski Febio Gutama Febriyanti, Maya Haifa, Rima HISBAN HAMID ARIFKI Ida Paulina Sormin Imas Maesaroh Indradi, Raden Bayu Intania, Ruri Irma Melyani Puspitasari Irma Rahayu Latarissa Irmansyah Irmansyah Ivan Pradipta Ivan Surya Pradipta Karina Erlianti Kennardi, Gabriel Bagus Keri Lestari Khaira, Syifa Komang Suma Triyasa Laniyati Hamijoyo, Laniyati LILY CYNTIA FAUZI Luki Yogaswara Yusuf Made Putra Semadhi Maisyarah, Intan Timur Maya Febriyanti Miftakh Nur Rahman Miswar Fattah Moses Prasetio Muhaimin Muhaimin Muhammad Fauzi Munir Alinu Mulki Mustikawati, Bunga Nadiya Nurul Afifah Nuning Nurcayani Peratiwi, Shafira Galuh Permatasari, Lany Indah Pratama, Muhammad Syawal Prayudi Santoso Putri Maharani Putri, Nazwa Septiriana Qolbina, Shofura Marsa Raden Maya Febriyanti Rendrayani, Farida Rimadani Pratiwi Rizki Rahmadi Pratama Rizky Abdulah Sahila, Elma N. M. R. Sartika Aprianti Shelly Iskandar Soemarie, Yulistia Budianti Syahrina, Nadira Alvi Tahara, Nabila Theresia Ratnadevi TIANA MILANDA Tina Rostinawati Widya Naftalia Wijasa Yudisia Ausi Yulistia Budianti Soemarie Yulistia Budianti Soemarie Yuni Elsa Hadisaputri Zakiyah, Neily Zelika Mega Ramadhania